Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies, a biopharmaceutical company, has announced that Novartis Pharma and Nordic Bioscience have completed recruitment for a multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen Technology to treat patients with osteoarthritis of the knee.
Subscribe to our email newsletter
The study, which will be used to support the filing with health authorities worldwide, includes more than 1,100 patients between 51 and 80 years old with a medical history and symptoms of knee osteoarthritis. The study will be conducted mainly in Europe and is estimated to complete in the second half of 2010.
Michael Novinski, president and CEO of Emisphere, said: “The problems associated with osteoarthritis will escalate as the population ages. This Phase III study aims at demonstrating that oral salmon calcitonin, in combination with our Eligen drug delivery technology, may contribute to solving this problem, and also shows that Emisphere is a valuable partner in drug development.”